Preclinical News and Research

RSS

Protein expression predicts postop NSCLC recurrence, survival

US-based researchers have identified a panel of 12 proteins that may help predict overall survival and the risk of recurrence in patients treated with surgery for non-small-cell lung cancer.

15 Apr 2014

Effects of PectaSol-C modified citrus pectin in prostate cancer patients to be studied in phase III trial

A phase III clinical trial conducted at the Meir Medical Center in Kfar-Saba, Israel is now recruiting participants to study the effects of dietary supplement PectaSol-C modified citrus pectin (MCP) in controlling prostate specific antigen (PSA) levels in prostate cancer patients.

15 Apr 2014

DesignMedix receives $3 million NIH grant to develop new anti-malarial drug

DesignMedix, Inc., a biotech startup with ties to Portland State University, received a grant for almost $3 million from the National Institutes of Health to continue development and manufacture of a new anti-malarial drug.

15 Apr 2014

Domain Therapeutics receives grant to support development of mGluR3 PAM for Parkinson’s disease

Domain Therapeutics, a biopharmaceutical company specializing in the research and development of new drug candidates targeting G protein-coupled receptors (GPCRs), today announces the receipt of a second grant of 230 000 dollars (USD) from The Michael J. Fox Foundation for Parkinson’s Research to support its metabotropic glutamate receptor type III (mGluR3) positive allosteric modulators (PAM) program.

15 Apr 2014

Researchers investigate role of microRNAs in breast cancer cells

Metastasis — the spreading of cancer cells from a primary tumor site to other parts of the body — generally leads to poorer outcomes for patients, so oncologists and researchers are constantly seeking new ways to detect and thwart this malicious process.

15 Apr 2014

Scientists discover how bacterium Y. pestis overwhelms lungs to cause pneumonic plague

Northwestern Medicine scientists are continuing to unravel the molecular changes that underlie one of the world's deadliest and most infamous respiratory infections.

15 Apr 2014

Ceritinib ‘highly active’ in advanced ALK-rearranged NSCLC

Phase I study findings suggest the investigational drug ceritinib is effective in patients with advanced non-small-cell lung cancer with anaplastic lymphoma kinase gene rearrangement, even in those who develop resistance to crizotinib.

14 Apr 2014

BioLineRx to initiate Phase 1/2 clinical trial on new drug candidate for CML treatment

BioLineRx, a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that Prof. Arnon Nagler, Director of the Hematology Division and Bone Marrow Transplantation Center at Sheba Medical Center, Israel, has received final regulatory approval to evaluate BioLineRx's BL-8040 as a treatment for chronic myeloid leukemia (CML) in a Phase 1/2 clinical study.

10 Apr 2014

Genkyotex’s GKT137831 reverses lung fibrosis in new model of idiopathic pulmonary fibrosis

Genkyotex, the leading developer of selective NOX enzyme inhibitors, announced today the publication of data showing that GKT137831, a first in class NOX1 and 4 inhibitor, was able to reverse lung fibrosis associated with aging in a new model of idiopathic pulmonary fibrosis.

10 Apr 2014

Stem cells culled from bone marrow may prove beneficial in stroke recovery

Stem cells culled from bone marrow may prove beneficial in stroke recovery, scientists at UC Irvine's Sue & Bill Gross Stem Cell Research Center have learned.

10 Apr 2014

Spero Therapeutics enters into antibiotics partnership with Roche

Spero Therapeutics, LLC, a biopharmaceutical company founded to develop novel therapies for treatment of bacterial infections, has entered into an antibiotics partnership with Roche.

9 Apr 2014

Study: Honokiol reduces proliferation of renal cell carcinoma

A new study shows that honokiol, a small molecule polyphenol extract derived from Magnolia officinalis bark, reduces proliferation of renal cell carcinoma.

9 Apr 2014

New lab at the Nencki Institute conducts research on neurodegenerative diseases

The Laboratory of Preclinical Studies of Higher Standard, the newest lab of the Neurobiology Center at the Nencki Institute in Warsaw, Poland, will conduct basic research aimed to explain molecular mechanisms responsible for neurodegenerative diseases.

9 Apr 2014

Researchers identify novel compound effective against drug-resistant lung cancer

Despite advances made in detecting and treating nonsmall cell lung cancer, its prognosis remains grim. Even patients whose cancers are caught at their earliest stage have only a 50 percent chance of five-year survival. This poor prognosis is due in part to the cancer's ability to resist treatment, rendering the chemotherapy ineffective.

9 Apr 2014

PeptiDream develops novel macrocyclic peptide inhibitor for treatment of multiple influenza strains

PeptiDream Inc., a public Tokyo-based biopharmaceutical company ("PeptiDream")( TOKYO:4587) announced today, in collaboration with The Tokyo Metropolitan Institute of Medical Science ("Tokyo Metropolitan Institute") the discovery and development of a novel macrocyclic peptide inhibitor for the treatment of multiple influenza strains.

8 Apr 2014

DelMar presents pre-clinical study data that evaluates activity of VAL-083 in drug-resistant NSCLC

DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar") today announced the presentation of new data in a poster entitled, "In vivo efficacy of VAL-083 in the treatment of non-small cell lung cancer." DelMar's data was presented on Sunday, April 6, 2014 during the Novel Cytotoxic Strategies Session at the 105th Annual Meeting of the American Association for Cancer Research (AACR) in San Diego.

8 Apr 2014

Curis and Debiopharm present data for Debio 0932 at Annual Meeting of AACR

Curis, Inc., an oncology focused company developing novel, targeted drug candidates for the treatment of human cancers, and Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology as well as companion diagnostics, today announced presentation of data for Debio 0932 at the Annual Meeting of the American Association for Cancer Research (AACR) that demonstrated synergy between Debio 0932 and various standard of care (SOC) agents in multiple in vitro and xenograft models of non-small cell lung cancer (NSCLC) and renal cell carcinoma (RCC).

8 Apr 2014

Combination therapy with MEK and BRAF inhibitors for anaplastic thyroid cancer proves effective

Researchers from the Jacks Laboratory at MIT's Koch Institute for Integrative Cancer Research (KI) have developed and characterized a genetically engineered mouse that successfully models progression from papillary thyroid cancer, which has an excellent prognosis, to anaplastic thyroid cancer (ATC), a highly lethal disease.

8 Apr 2014

Researchers show Elafin protein plays key role against inflammatory reaction typical of celiac disease

Scientists from INRA and INSERM (France) in collaboration with scientists from McMaster University (Canada) and the Ecole polytechnique fédérale of Zurich (Switzerland) have shown that Elafin, a human protein, plays a key role against the inflammatory reaction typical of celiac disease (gluten intolerance).

8 Apr 2014

Magnetic nanoparticle (mNP) hyperthermia in breast cancer treatment

In a presentation exploring the promise of magnetic nanoparticle (mNP) hyperthermia in breast cancer treatment, Dartmouth researcher P. Jack Hoopes, DMV, PhD, reviewed preclinical studies conducted at Norris Cotton Cancer Center and discuss plans for early-phase clinical studies in humans at the annual meeting of the American Association for Cancer Research (AACR).

8 Apr 2014

Preclinical News and Research

Protein expression predicts postop NSCLC recurrence, survival

Effects of PectaSol-C modified citrus pectin in prostate cancer patients to be studied in phase III trial

DesignMedix receives $3 million NIH grant to develop new anti-malarial drug

Domain Therapeutics receives grant to support development of mGluR3 PAM for Parkinson’s disease

Researchers investigate role of microRNAs in breast cancer cells

Scientists discover how bacterium Y. pestis overwhelms lungs to cause pneumonic plague

Ceritinib ‘highly active’ in advanced ALK-rearranged NSCLC

BioLineRx to initiate Phase 1/2 clinical trial on new drug candidate for CML treatment

Genkyotex’s GKT137831 reverses lung fibrosis in new model of idiopathic pulmonary fibrosis

Stem cells culled from bone marrow may prove beneficial in stroke recovery

Spero Therapeutics enters into antibiotics partnership with Roche

Study: Honokiol reduces proliferation of renal cell carcinoma

New lab at the Nencki Institute conducts research on neurodegenerative diseases

Researchers identify novel compound effective against drug-resistant lung cancer

PeptiDream develops novel macrocyclic peptide inhibitor for treatment of multiple influenza strains

DelMar presents pre-clinical study data that evaluates activity of VAL-083 in drug-resistant NSCLC

Curis and Debiopharm present data for Debio 0932 at Annual Meeting of AACR

Combination therapy with MEK and BRAF inhibitors for anaplastic thyroid cancer proves effective

Researchers show Elafin protein plays key role against inflammatory reaction typical of celiac disease

Magnetic nanoparticle (mNP) hyperthermia in breast cancer treatment

New Approach Methodologies, the 3Rs and Multimodal Imaging in Preclinical Research - eBook eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics